Patents by Inventor Audrey Shaw
Audrey Shaw has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20250228828Abstract: The application describes treatment of hepatic encephalopathy using gastrointestinal specific antibiotics. One example of a gastrointestinal specific antibiotic is rifaximin. The instant application also provides methods for determining if a subject has a neurological condition or hepatic encephalopathy by determining the critical flicker frequency and/or the venous ammonia level of the subject at two or more time points. The invention further provides methods for treating these subjects.Type: ApplicationFiled: April 1, 2025Publication date: July 17, 2025Applicant: Salix Pharmaceuticals, Inc.Inventors: William FORBES, Kunal Merchant, Enoch Bortey, Audrey Shaw
-
Patent number: 12285414Abstract: The application describes treatment of hepatic encephalopathy using gastrointestinal specific antibiotics. One example of a gastrointestinal specific antibiotic is rifaximin. The instant application also provides methods for determining if a subject has a neurological condition or hepatic encephalopathy by determining the critical flicker frequency and/or the venous ammonia level of the subject at two or more time points. The invention further provides methods for treating these subjects.Type: GrantFiled: February 28, 2022Date of Patent: April 29, 2025Assignee: Salix Pharmaceuticals, Inc.Inventors: William Forbes, Kunal Merchant, Enoch Bortey, Audrey Shaw
-
Publication number: 20200061032Abstract: The application describes treatment of hepatic encephalopathy using gastrointestinal specific antibiotics. One example of a gastrointestinal specific antibiotic is rifaximin. The instant application also provides methods for determining if a subject has a neurological condition or hepatic encephalopathy by determining the critical flicker frequency and/or the venous ammonia level of the subject at two or more time points. The invention further provides methods for treating these subjects.Type: ApplicationFiled: April 23, 2019Publication date: February 27, 2020Inventors: William Forbes, Kunal Merchant, Enoch Bortey, Audrey Shaw
-
Patent number: 10314828Abstract: The application describes treatment of hepatic encephalopathy using gastrointestinal specific antibiotics. One example of a gastrointestinal specific antibiotic is rifaximin. The instant application also provides methods for determining if a subject has a neurological condition or hepatic encephalopathy by determining the critical flicker frequency and/or the venous ammonia level of the subject at two or more time points. The invention further provides methods for treating these subjects.Type: GrantFiled: November 28, 2017Date of Patent: June 11, 2019Assignee: Salix Pharmaceuticals, LtdInventors: William Forbes, Kunal Merchant, Enoch Bortey, Audrey Shaw
-
Publication number: 20180271842Abstract: The application describes treatment of hepatic encephalopathy using gastrointestinal specific antibiotics. One example of a gastrointestinal specific antibiotic is rifaximin. The instant application also provides methods for determining if a subject has a neurological condition or hepatic encephalopathy by determining the critical flicker frequency and/or the venous ammonia level of the subject at two or more time points. The invention further provides methods for treating these subjects.Type: ApplicationFiled: November 28, 2017Publication date: September 27, 2018Inventors: William Forbes, Kunal Merchant, Enoch Bortey, Audrey Shaw
-
Patent number: 9855254Abstract: The application describes treatment of hepatic encephalopathy using gastrointestinal specific antibiotics. One example of a gastrointestinal specific antibiotic is rifaximin. The instant application also provides methods for determining if a subject has a neurological condition or hepatic encephalopathy by determining the critical flicker frequency and/or the venous ammonia level of the subject at two or more time points. The invention further provides methods for treating these subjects.Type: GrantFiled: July 18, 2016Date of Patent: January 2, 2018Assignee: Salix Pharmaceuticals, Ltd.Inventors: William Forbes, Kunal Merchant, Enoch Bortey, Audrey Shaw
-
Publication number: 20170042864Abstract: The application describes treatment of hepatic encephalopathy using gastrointestinal specific antibiotics. One example of a gastrointestinal specific antibiotic is rifaximin. The instant application also provides methods for determining if a subject has a neurological condition or hepatic encephalopathy by determining the critical flicker frequency and/or the venous ammonia level of the subject at two or more time points. The invention further provides methods for treating these subjects.Type: ApplicationFiled: July 18, 2016Publication date: February 16, 2017Inventors: William Forbes, Kunal Merchant, Enoch Bortey, Audrey Shaw
-
Patent number: 9421195Abstract: The application describes treatment of hepatic encephalopathy using gastrointestinal specific antibiotics. One example of a gastrointestinal specific antibiotic is rifaximin. The instant application also provides methods for determining if a subject has a neurological condition or hepatic encephalopathy by determining the critical flicker frequency and/or the venous ammonia level of the subject at two or more time points. The invention further provides methods for treating these subjects.Type: GrantFiled: June 10, 2013Date of Patent: August 23, 2016Assignee: Salix Pharmaceuticals, LtdInventors: William Forbes, Kunal Merchant, Enoch Bortey, Audrey Shaw
-
Patent number: 8642573Abstract: The application describes treatment of hepatic encephalopathy using gastrointestinal specific antibiotics. One example of a gastrointestinal specific antibiotic is rifaximin. The instant application also provides methods for determining if a subject has a neurological condition or hepatic encephalopathy by determining the critical flicker frequency and/or the venous ammonia level of the subject at two or more time points. The invention further provides methods for treating these subjects.Type: GrantFiled: January 9, 2013Date of Patent: February 4, 2014Assignee: Salix Pharmaceuticals, LtdInventors: William Forbes, Kunal Merchant, Enoch Bortey, Audrey Shaw
-
Publication number: 20130345166Abstract: The application describes treatment of hepatic encephalopathy using gastrointestinal specific antibiotics. One example of a gastrointestinal specific antibiotic is rifaximin. The instant application also provides methods for determining if a subject has a neurological condition or hepatic encephalopathy by determining the critical flicker frequency and/or the venous ammonia level of the subject at two or more time points. The invention further provides methods for treating these subjects.Type: ApplicationFiled: June 10, 2013Publication date: December 26, 2013Inventors: William Forbes, Kunal Merchant, Enoch Bortey, Audrey Shaw
-
Publication number: 20110071103Abstract: The application describes treatment of hepatic encephalopathy using gastrointestinal specific antibiotics. One example of a gastrointestinal specific antibiotic is rifaximin. The instant application also provides methods for determining if a subject has a neurological condition or hepatic encephalopathy by determining the critical flicker frequency and/or the venous ammonia level of the subject at two or more time points. The invention further provides methods for treating these subjects.Type: ApplicationFiled: December 10, 2010Publication date: March 24, 2011Applicant: SALIX PHARMACEUTICALS, LTD.Inventors: William Forbes, Kunal Merchant, Enoch Bortey, Audrey Shaw
-
Publication number: 20110035232Abstract: Treatment of hepatic encephalopathy using gastrointestinal specific antibiotics is disclosed. One example of a gastrointestinal specific antibiotic is rifaximin. The instant application also provides methods for determining if a subject has a neurological condition or hepatic encephalopathy by determining the critical flicker frequency and/or the venous ammonia level of the subject at two or more time points. The further provided are methods for treating these subjects.Type: ApplicationFiled: June 2, 2010Publication date: February 10, 2011Applicant: SALIX PHARMACEUTICALS, LTD.Inventors: William Forbes, Kunal Merchant, Enoch Bortey, Audrey Shaw
